Having two drugs on the top of the most expensive drugs list is a shame. It is clear that insurance companies increase premiums to all others for select few treated. Time to leave Sarepta.
Pharma companies disguise themselves as gentle and caring lambs working hard to save lives. The scale of money involved in rare diseases cure is disproportional to resulting benefits. This is a cover up for industrial elites to live a safe and wealthy existence, whereas their technology lags behind and development progress is much slower than in other industries. Increasingly the work is offshored and the pharma companies mostly add to the cost being the wealth-consuming part in the chain. In contrast to rare diseases and gene and cell therapy that may be focused on small numbers of patients, vaccines are directed towards large populations and must be developed quickly. Being from vaccine field we have little respect for people who doodle for years to develop some marginal drugs and getting rich in the process
2025 Davos is coming. The company is also enamored with Global Lighthouse Network by World Economic Forum. We know what that Forum represents. USA has DeepState. WEF is DeepGlobalism.
At JPM Conf. Biomarin presentation did not convince investors and stock has tanked.
Interesting that CEO brought his new set of upper management and only Brian from the old set.
This shows that old management is on its way out as someone indicated on this site. Would such replacement help the company? New management may not understand specifics of future portfolio. Or they are there to complete M&A deal.
Layoffs!
Cell therapy in question.
Gilead is in retreat, so how about Kite?
Cell therapy is like a laboratory and clinical procedure development, not a typical pharma drug development. Often at enormous cost. And a market size and economics?
Genentech under Roche is diminishing continually. Manufacturing related jobs are practically only in Oregon. There are fewer opportunities in R&D in SSF. Wonder what is going to be shut down next. Layoffs are probable in 2025.